Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.80 |
| ▸ | RAB9A | P51151 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796007 | 0.88 | TAAR1 (0.69) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL12218241 | 0.84 | POLB (1.00) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL28465013 | 0.82 | NPC1 (0.81) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL1750778 | 0.82 | KMT2A (0.71) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL3455686 | 0.78 | MEN1 (0.65) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL6396043 | 0.77 | KMT2A (0.71) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL23083281 | 0.77 | NPC1 (0.72) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL14670856 | 0.76 | HPGD (0.70) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL6290073 | 0.76 | HPGD (0.70) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL6290075 | 0.76 | HPGD (0.70) | NPC1RAB9AKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-1996566-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106016-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | NPC1 1506/4885RAB9A 1468/4885KMT2A 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.